Is Soaring Invitae Stock a Smart Buy Now?
Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. The medical genetics company is still losing money, but it's starting to look like it can achieve a sustainable level of profitability.
Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.
Invitae is trying to aggregate all the world's genetic tests into a single service, an enormous endeavor that many pessimistic short sellers don't believe is possible. In their defense, the company is still a long way from profitability.
Source Fool.com
